DrugBiological
Patritumab deruxtecan clinical trials
Also written U3-1402 and MK-1022.
Keep track of what changes. Save the patritumab deruxtecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- HER3-DXd
- 11
Studies by the year they started
19 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 7
Daiichi Sankyo (6) · Merck Sharp & Dohme LLC (5) · SOLTI Breast Cancer Research Group (2) · SCRI Development Innovations, LLC (1) · MedSIR (1) · Daiichi Sankyo Co., Ltd. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Samsung Medical Center (1)
Often tested with
Tested in the same studies.
Ramucirumab (1) · Paclitaxel (1) · Sacituzumab tirumotecan (1)
Studies
Open first, then newest update. How each study uses patritumab deruxtecan is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Patritumab deruxtecan
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06941272Written as Patritumab Deruxtecan
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 2Daiichi SankyoNCT06172478Written as HER3-DXd
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Daiichi SankyoNCT07701941Written as Patritumab deruxtecan
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Patritumab deruxtecan
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06445972Written as HER3-DXd
- Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04965766Written as U3-1402
- Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusionRecruitingPhase 2Samsung Medical CenterNCT06383884Written as Patritumab Deruxtecan
- Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06596694Written as Patritumab deruxtecan
- HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingPhase 2Daiichi SankyoNCT04619004Written as Patritumab Deruxtecan (Fixed dose)
- HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyActive, not recruitingPhase 3Daiichi SankyoNCT05338970Written as Patritumab Deruxtecan
- A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerCompletedPhase 2SCRI Development Innovations, LLCNCT04699630Written as U3-1402
- HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal DiseaseCompletedPhase 2MedSIRNCT05865990Written as Patritumab deruxtecan
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruitingPhase 1Daiichi SankyoNCT03260491Written as HER3-DXd (FL-DP)
- A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain MetastasesWithdrawnPhase 2Mustafa Khasraw, MBChB, MD, FRCP, FRACPNCT05620914Written as Patritumab deruxtecan
- A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal CancerTerminatedPhase 2Daiichi SankyoNCT04479436Written as Patritumab Deruxtecan
- Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast CancerCompletedPhase 1/2Daiichi Sankyo Co., Ltd.NCT02980341Written as Patritumab Deruxtecan
- NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE TrialActive, not recruitingPhase 2SOLTI Breast Cancer Research GroupNCT05569811Written as Patritumab deruxtecan
- A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 ExpressionActive, not recruitingEarly Phase 1SOLTI Breast Cancer Research GroupNCT04610528Written as U3 1402
Given in every arm · 7 — patritumab deruxtecan is usual care beside what is tested
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Written as Patritumab deruxtecan
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06731907Written as HER3-DXd
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as Patritumab Deruxtecan
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07286149Written as Patritumab deruxtecan
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06298084Written as Patritumab deruxtecan
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as HER3-DXd
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingPhase 1Daiichi SankyoNCT04676477Written as HER3-DXd
Codes
What other systems call patritumab deruxtecan · ClinicalTrials.gg INT001428
- MeSH (NLM) C000710748patritumab deruxtecanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3XPI7EG4W8PATRITUMAB DERUXTECANConfirmed FDA, NLM
- NCI Thesaurus C136987Patritumab DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710748 | patritumab deruxtecan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3XPI7EG4W8 | PATRITUMAB DERUXTECAN | Confirmed FDA, NLM |
| NCI Thesaurus | C136987 | Patritumab Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.